Innovative lead discovery strategies for tropical diseases
暂无分享,去创建一个
[1] S. Ōmura,et al. The life and times of ivermectin — a success story , 2004, Nature Reviews Microbiology.
[2] A. Anderson. The process of structure-based drug design. , 2003, Chemistry & biology.
[3] L. Maes,et al. Anti-infective potential of natural products: how to develop a stronger in vitro 'proof-of-concept'. , 2006, Journal of ethnopharmacology.
[4] R. W. Hansen,et al. The price of innovation: new estimates of drug development costs. , 2003, Journal of health economics.
[5] R. Ridley. Research on infectious diseases requires better coordination , 2004, Nature Medicine.
[6] R. Frank,et al. New estimates of drug development costs. , 2003, Journal of health economics.
[7] David Alland,et al. Targeting Tuberculosis and Malaria through Inhibition of Enoyl Reductase , 2003, Journal of Biological Chemistry.
[8] J. Bryans,et al. Academia–industry partnerships in drug discovery , 2006, Expert opinion on drug discovery.
[9] Katherine A Brown,et al. Protein farnesyl and N-myristoyl transferases: piggy-back medicinal chemistry targets for the development of antitrypanosomatid and antimalarial therapeutics. , 2003, Molecular and biochemical parasitology.
[10] K. Bush,et al. Taking inventory: antibacterial agents currently at or beyond phase 1. , 2004, Current opinion in microbiology.
[11] Makedonka Mitreva,et al. Comparative genomics of nematodes. , 2005, Trends in genetics : TIG.
[12] Andrew K. Jones,et al. Model organisms: Chemistry-to-gene screens in Caenorhabditis elegans , 2005, Nature Reviews Drug Discovery.
[13] Daniel Nilsson,et al. Comparative Genomics of Trypanosomatid Parasitic Protozoa , 2005, Science.
[14] Ross L Stein,et al. High-Throughput Screening in Academia: The Harvard Experience , 2003, Journal of biomolecular screening.
[15] Pickett,et al. Computational methods for the prediction of 'drug-likeness' , 2000, Drug discovery today.
[16] J. McCarter,et al. RNAi-based discovery and validation of new drug targets in filarial nematodes. , 2005, Trends in parasitology.
[17] Harren Jhoti,et al. High-throughput crystallography for lead discovery in drug design , 2002, Nature Reviews Drug Discovery.
[18] A. Hopkins,et al. The druggable genome , 2002, Nature Reviews Drug Discovery.
[19] L. Chitsulo,et al. Strategic emphases for tropical diseases research: a TDR perspective. , 2002, Trends in microbiology.
[20] Jaideep P. Sundaram,et al. Health Innovation Networks to Help Developing Countries Address Neglected Diseases , 2005, Science.
[21] G. V. Paolini,et al. Global mapping of pharmacological space , 2006, Nature Biotechnology.
[22] Jürgen Bajorath,et al. Integration of virtual and high-throughput screening , 2002, Nature Reviews Drug Discovery.
[23] Els Torreele,et al. Drug development for neglected diseases: a deficient market and a public-health policy failure , 2002, The Lancet.
[24] Christian Scheurer,et al. Identification of an antimalarial synthetic trioxolane drug development candidate , 2004, Nature.
[25] Richard T Eastman,et al. Protein farnesyl transferase inhibitors for the treatment of malaria and African trypanosomiasis. , 2005, Current opinion in investigational drugs.
[26] Beth Apsel,et al. Discovery of Trypanocidal Compounds by Whole Cell HTS of Trypanosoma brucei , 2006, Chemical biology & drug design.
[27] P. Rosenthal,et al. Antimalarial drug discovery: old and new approaches , 2003, Journal of Experimental Biology.
[28] J. Barrett,et al. Antibiotics: where did we go wrong? , 2005, Drug discovery today.
[29] Mary Moran,et al. A Breakthrough in R&D for Neglected Diseases: New Ways to Get the Drugs We Need , 2005, PLoS Medicine.
[30] Li Li,et al. PlasmoDB: the Plasmodium genome resource. A database integrating experimental and computational data , 2003, Nucleic Acids Res..
[31] R. Pink,et al. Opportunities and Challenges in Antiparasitic Drug Discovery , 2005, Nature Reviews Drug Discovery.
[32] C. R. Bagnell,et al. Distribution and quantitation of the anti-trypanosomal diamidine 2,5-bis(4-amidinophenyl)furan (DB75) and its N-methoxy prodrug DB289 in murine brain tissue. , 2004, Acta tropica.
[33] D. Fairlie,et al. Anti-malarial effect of histone deacetylation inhibitors and mammalian tumour cytodifferentiating agents. , 2000, International journal for parasitology.
[34] David A. Fidock,et al. Antimalarial drug discovery: efficacy models for compound screening , 2004, Nature Reviews Drug Discovery.
[35] Bindu Gajria,et al. PlasmoDB: The Plasmodium Genome Resource , 2005 .
[36] Yongyuth Yuthavong,et al. Insights into antifolate resistance from malarial DHFR-TS structures , 2003, Nature Structural Biology.
[37] M. Cotreau,et al. The Antiparasitic Moxidectin: Safety, Tolerability, and Pharmacokinetics in Humans , 2003, Journal of clinical pharmacology.
[38] Jonathan E. Allen,et al. Genome sequence of the human malaria parasite Plasmodium falciparum , 2002, Nature.
[39] Wim G J Hol,et al. Drugs to Combat Tropical Protozoan Parasites , 2002, Science.
[40] P. Rathod,et al. High-throughput Screening for Potent and Selective Inhibitors of Plasmodium falciparum Dihydroorotate Dehydrogenase* , 2005, Journal of Biological Chemistry.
[41] J. McKerrow,et al. A Cysteine Protease Inhibitor Protects Dogs from Cardiac Damage during Infection by Trypanosoma cruzi , 2005, Antimicrobial Agents and Chemotherapy.
[42] Samiul Hasan,et al. Prioritizing Genomic Drug Targets in Pathogens: Application to Mycobacterium tuberculosis , 2006, PLoS Comput. Biol..
[43] Andrej Sali,et al. Finding Cures for Tropical Diseases: Is Open Source an Answer? , 2004, PLoS medicine.
[44] Current strategies in the search for novel antiparasitic agents. , 1999, International journal for parasitology.
[45] J. Guzman,et al. The New Landscape of Neglected Disease Drug Development , 2005 .
[46] A. Hopkins,et al. Navigating chemical space for biology and medicine , 2004, Nature.
[47] S. Nwaka. Drug discovery and beyond: the role of public-private partnerships in improving access to new malaria medicines. , 2005, Transactions of the Royal Society of Tropical Medicine and Hygiene.
[48] J. McKerrow. Designing Drugs for Parasitic Diseases of the Developing World , 2005, PLoS medicine.
[49] Jon Cohen. Gates Foundation Picks Winners in Grand Challenges in Global Health , 2005, Science.
[50] E. Brown. Screening in Academe: A Perspective on Implementation of University-Based Small Molecule Screening , 2003, Journal of biomolecular screening.
[51] W. Gutteridge. TDR collaboration with the pharmaceutical industry. , 2006, Transactions of the Royal Society of Tropical Medicine and Hygiene.
[52] F. Cohen,et al. The Impact of Whole Genome Sequence Data on Drug Discovery—A Malaria Case Study , 2001, Molecular medicine.
[53] Phillip Gribbon,et al. High-throughput drug discovery: what can we expect from HTS? , 2005, Drug discovery today.
[54] Jeffrey D Sachs,et al. Incorporating a Rapid-Impact Package for Neglected Tropical Diseases with Programs for HIV/AIDS, Tuberculosis, and Malaria , 2006, PLoS medicine.
[55] Jun O. Liu,et al. A clinical drug library screen identifies astemizole as an antimalarial agent , 2006, Nature chemical biology.
[56] Solomon Nwaka,et al. Science & society: Virtual drug discovery and development for neglected diseases through public–private partnerships , 2003, Nature Reviews Drug Discovery.